

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Non-Preferred Single Agent NSAID Step Therapy

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Comments	Quantity Limit
all generically available Ibuprofen (except Infants Advil 50mg/1.25 ML)	Preferred	May be subject to quantity limits.
Diclofenac Potassium		
Diclofenac Sodium		
Etodolac, Etodolac ER		
Fenoprofen Calcium		
Flurbiprofen		
Indomethacin		
Ketoprofen		
Ketorolac Tromethamine		
Meclofenamate Sodium		
Meloxicam		
Nabumetone		
Naproxen Sodium all generic formulations		
Naproxen		
Naproxen DS 550mg		
Oxaprozin		
Piroxicam		
Sulindac		
Tolmetin Sodium		
all MSB NSAIDs		
Celecoxib (brand and generic)		

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Fenoprofen (SSB)		
Indocin Suppository		
Indocin suspension		
Nalfon		
Naprelan		
Naproxen CR		
Naproxen Sodium ER		
Ponstel (Mefenamic brand and generic)		
Qmiiz ODT		
Relafen DS		
Sprix Nasal Spray – Brand and Generic		
Tivorbex – Brand and Generic		
Vivlodex		
Zipsor		
Zorvolex		

APPROVAL CRITERIA

Requests for a non-preferred single agent NSAID may be approved if the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to two (2) preferred single agent oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDs);

OR

- II. Requested agent is indomethacin suppositories; **AND**
- III. Individual is unable to take oral Non-Steroidal Anti-Inflammatory Drugs (NSAID);

OR

- IV. Requested agent is Celebrex (celecoxib); **AND**
- V. One of the following:
 - a. Individual has history of a gastrointestinal disorder (such as, ulcer, gastritis); **OR**
 - b. Individual has a diagnosis of Desmoid tumors (aggressive fibromatosis) (NCCN 2A);

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

OR

VI. The preferred NSAIDs are not FDA-approved and do not have an accepted off-label use per the off-label policy for the prescribed indication and the non-preferred agent does.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: March 17, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.